Cancer Clinical Trials:
Glioblastoma Protocols

  • LS-P-CENTRIC: Cilengitide for subjects with newly diagnosed GBM and methylated MGMT gene promoter – a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standart treatment (tem with concomitant radiation theraphy, following by tem maintenance therapy) vs. standard treatment alone
    Principal Investigator: Suriya Jeyapalan, MD
    Sites: Rhode Island Hospital
  • RTOG 0825: Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma.
    Principal Investigator: Brigid O’Connor, MD, PhD
    Site: Rhode Island Hospital
  • RTOG 0929: A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant)
    Principal Investigator: Heinrich Elinzano, MD
    Sites: Rhode Island Hospital

For more information about these clinical trials and how to participate, please call 401-444-HOPE (4673). For general information about clinical trials please visit the National Cancer Institute.

Other Clinical Trials and Noteworthy Treatments for Brain Tumors in the Rhode Island area.

____________________________________

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

Keywords: Observation, Radiation, Chemotherapy

Phase: Phase 2

Treatment ID#s: VT1508 NCT00027846

Age Group: Pediatric Only

Min Karnofsky Score:  10: Fatal processes progressing rapidly

Conditions: Newly Diagnosed: Y
Recurrent: Y
Prior Surgery is Allowed
Prior Radiation is Not Allowed
Prior Chemotherapy is Not Allowed

Patients must be greater than twelve months and less than twenty one years of age. Histologically confirmed intracranial ependymoma. No evidence of spread of disease beyond the primary site. No prior therapy beyond surgery and corticosteroids.

Tumor Types: Ependyoma

Comments: Ependymoma is a relatively rare type of central nervous system (CNS) tumor. Standard treatment for ependymoma is surgical removal followed by post operative radiation therapy directed at the primary site. Young children, less than three years of age, typically have not received radiation therapy, but instead have received multi-agent chemotherapy in an effort to delay radiation therapy. Patients with ependymoma who have incomplete resections and those who delay radiation therapy with chemotherapy have poor overall survival. With the help of the Children’s Oncology Group (COG), investigators want to answer important questions with the hope of improving the outcomes (improved survival with reduced side effects) for these patients by increasing the rate of complete resection and by using conformal radiation therapy for children older than 12 months of age. Researchers will investigate the use of chemotherapy in children with incomplete resections prior to second surgery, conformal radiation therapy, and no therapy after surgery for completely resected supratentorial, differentiated ependymoma For more information:

www.stjude.org/brain-tumors

Treatment Type: Chemotherapy
Radiation.

Location:

Rhode Island Hospital

Sam W. Lew, MD

Providence, RI 02903

401-444-5171

Source:

http://virtualtrials.com/trialdetails2.cfm?id=150801005

____________________________________

Treatment Name:  Phase II Study of Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiotherapy With or Without Peripheral Blood Stem Cell Rescue in Patients With Intracranial Non-Germinomatous Germ Cell Tumors

Keywords: Stem cell transplant

Phase: Phase 2

Treatment ID#s: VT619 NCT00047320

Age Group: Adult and Pediatric

Min Karnofsky Score: 10: Fatal processes progressing rapidly

Conditions: Newly Diagnosed: Y
Recurrent: Y
Prior Surgery is Allowed
Prior Radiation is Not Allowed
Prior Chemotherapy is Not Allowed

Tumor Types: Germ Cell Tumors

Comments: This is a multi-institutional clinical research study which is aimed at improving disease-free and overall survival for patients diagnosed with a non-germinoma germ cell tumor (NGGCT), a malignant brain tumor formed by cancerous germ cells, by using multi-agent chemotherapy followed by radiotherapy. Patients will initially receive four 3-week chemotherapy cycles utilizing a three-drug regimen consisting of Cisplatin, Etoposide and Ifosfamide. If the patient has a complete response (CR), i.e., complete disappearance of the tumor after these 4 cycles, they will then proceed to radiation therapy. If there is still residual disease after 4 cycles of the initial chemotherapy, a second look surgery may be considered. If second surgery is performed and there is no detectable residual disease, the patient will receive radiation therapy. If there is residual tumor detected either by an MRI scan or the presence of raised tumor markers in the blood or cerebrospinal fluid after chemotherapy and second surgery (when performed), the patient will receive an additional regimen of two cycles of dose-intensified chemotherapy (Cyclophosphamide and Carboplatin) administered with the support of healthy peripheral blood stem cells.

Treatment Type: Chemotherapy

Rhode Island Hospital

Sam W. Lew, MD

Providence, RI 02903

Phone:  401-444-5171